PD1/PDL1 clinical trials adapt to a growing landscape of patients resistant to PDx
Nat Rev Drug Discov
.
2023 Dec;22(12):944-945.
doi: 10.1038/d41573-023-00179-6.
Authors
Ana Rosa Saez-Ibañez
,
Erin Sommers
,
Samik Upadhaya
,
Jay Campbell
PMID:
37914811
DOI:
10.1038/d41573-023-00179-6
No abstract available
Publication types
News
MeSH terms
B7-H1 Antigen*
Humans
Programmed Cell Death 1 Receptor*
Substances
B7-H1 Antigen
Programmed Cell Death 1 Receptor